Posted by Michael Wonder on 02 Aug 2021
Benlysta now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
30 July 2021 - Benlysta (belimumab) has been approved in Canada for the treatment of active lupus nephritis in adult patients.
Benlysta is available as an intravenous infusion and a subcutaneous injection.
Benlysta has been available in Canada as an intravenous infusion since 2011 to reduce disease activity in adult patients with active, autoantibody-positive, systemic lupus erythematosus.
